LANGUAGE
KOREAN
ENGLISH
LOCATION
COMPANY
R&D
R&D Institute
GMP Center
Clinical Development Status
Publications
PRODUCTS
1st Generation
Overview
CARTISTEM
®
PNEUMOSTEM
®
2nd Generation
Overview
SMUP-IA-01
SMUP-IV-01
R&D Inquiries
BUSINESS
CDMO
Quality System
CDMO Service
Quality Control
Global CDMO
CDMO Inquiries
CELLTREE Cord Blood Bank
MOVITA Nutritional Supplements
IR
Stock Information
Disclosure
Financial Information
IR Inquiries
PR
MEDIPOST on Media
Corporate Brochure
CONTACT US
Customer Center
R&D Inquiries
CDMO Inquiries
IR Inquiries
Search Results
MEDIPOST Clears Phase II Clinical Trial Approval for CARTISTEM in Japan
2019/12/09
MEDIPOST Receives Approval for Phase III Clinical Trial of CARTISTEM for the Tre…
2019/12/03
MEDIPOST to Expand the GMP facility to increase manufacturing capacity for CARTI…
2019/11/14
MEDIPOST Registers the Chinese Patent for a Mesenchymal Stem Cell Culture Method
2019/10/23
MEDIPOST Treats First Patient with Injectable Cell Therapeutic for Knee Osteoart…
2019/10/17
MEDIPOST’s PNEUMOSTEM Receives Fast Track Designation from the US FDA
2019/08/22
MEDIPOST Registers European Patent for the Mesenchymal Stem Cell Culture Method
2019/07/24
MEDIPOST Registers the Canadian Patent for a Mesenchymal Stem Cell Culture Metho…
2019/06/26
Disclosure
2019/06/10
Corporate Brochure
2019/06/04
CARTISTEM®
2019/06/04
Inquiries on Stem Cell Products
2019/06/04
Previous
1
2
3
4
5
6
7
…
14
Next
Menu